Attendees who purchased access to the 2016 Annual Meeting webcast were sent login information on May 11, 2016.

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 13 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 10 11 12 13 presentations: 1 to 25 of 306
Immuno-oncology Clinical Trials I
Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL)
Michael Postow
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Discussant
Padmanee Sharma
UT MD Anderson Cancer Center, Houston, TX, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
KEYNOTE-006: PD-L1 expression and efficacy in patients (Pts) treated with pembrolizumab (pembro) vs ipilimumab (IPI) for advanced melanoma
Matteo Carlino
Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Wentworthville, Australia
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Discussant
Charles G. Drake
Johns Hopkins Kimmel Comp. Cancer Center, Baltimore, MD, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
A phase I study of an HLA-DPB1*0401-restricted T-cell receptor targeting MAGE-A3 for patients with metastatic cancer
Yong-Chen Lu
National Institutes of Health, Bethesda, MD, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial
F. Stephen Hodi
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Discussant
Jedd D Wolchok
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Precision Medicine Early Clinical Trials
Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors
Jayesh Desai
Royal Melbourne Hospital, Melbourne, Australia
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Discussant
Udai Banerji
Inst. of Cancer Research, Sutton, United Kingdom
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Crizotinib achieves objective responses and long-lasting disease control in patients (pts) with metastatic papillary renal cell carcinoma type 1 (PRCC1) with somatic MET mutations. EORTC phase II trial 90101 "CREATE"
Patrick Schoffski
University Hospitals Leuven - Department of General Medical Oncology, Leuven, Belgium
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Discussant
Ravi Salgia
City of Hope, Duarte, CA, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results
Alexander Drilon
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions
David S Hong
MD Anderson Cancer Center, Houston, TX, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Discussant
Leena Gandhi
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Stem Cells in Cancer
Leukemic stem cells lie at the origin of AML relapse
John E. Dick
Univ. of Toronto, Toronto, ON, Canada
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
Stem Cells in Cancer
Niche and metastasis intiation
Ilaria Malanchi
Cancer Research UK, London, United Kingdom
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
Stem Cells in Cancer
Repopulation of cancer stem cells in therapeutic resistance
Keith S. Chan
Baylor College of Medicine, Houston, TX, United States
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
Stem Cells in Cancer
Mammary stem cells and breast cancer
Rama Khokha
Univ. of Toronto Ontario Cancer Inst., Toronto, ON, Canada
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
Large Animal Models for Solid Tumor Oncology
Transitional, technical, and biological approaches and advances to address unmet clinical needs
Lawrence B. Schook
University of Illinois at Urbana-Champaign, Urbana, IL, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Large Animal Models for Solid Tumor Oncology
Unmet clinical needs in oncology: The value of large animal models
George J. Weiner
University of Iowa Holden Comp. Cancer Center, Iowa City, IA, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Large Animal Models for Solid Tumor Oncology
The new pig on the block: Genome editing in cancer models
Angelika Schnieke
Technical University of Munich, Freising, Germany
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Large Animal Models for Solid Tumor Oncology
Organoid models and systems biology: From mouse to human
Michael M. Shen
Columbia University College of Physicians & Surgeons, New York, NY, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Molecular Pathology 101-- How to Optimize and Validate Immunohistochemical and In Situ Hybridization Assays: Pitfalls, Pearls and Power
Invited Speaker
Angelo M. De Marzo
John Hopkins University School of Medicine, Baltimore, MD, United States
from AACR Annual Meeting 2016 on April 17, 2016 7:00 AM-8:00 AM
Precision Checkpoint Immunotherapy
Immune checkpoints limiting responses to cancer
Gordon Freeman
Dana Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:00 PM
Precision Checkpoint Immunotherapy
Selectable markers for checkpoint inhibitor immunotherapy
Janis M. Taube
Johns Hopkins University, Baltimore, MD, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:00 PM
<< first | < prev page: of 13 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 10 11 12 13 presentations: 1 to 25 of 306